US Bancorp
AQST icon

US Bancorp’s Aquestive Therapeutics AQST Stock Holding History

US Bancorp’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5K Buy
2,530
+247
+11% +$1.04K ﹤0.01% 3430
2026
Q1 		$9.47K Sell
2,283
-1,967
-46% -$7.98K ﹤0.01% 3379
2025
Q4 		$27.5K Buy
4,250
+2,000
+89% +$12.5K ﹤0.01% 2948
2025
Q3 		$12.6K Hold
2,250
– – ﹤0.01% 3246
2025
Q2 		$7.45K Hold
2,250
– – ﹤0.01% 3516
2025
Q1 		$6.53K Hold
2,250
– – ﹤0.01% 3579
2024
Q4 		$8.01K Hold
2,250
– – ﹤0.01% 3498
2024
Q3 		$11.2K Buy
+2,250
New +$8.76K ﹤0.01% 3328

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

US Bancorp's AQST Position: Q2 2026 in Review

US Bancorp increased its Aquestive Therapeutics (AQST) stake by 11% in Q2 2026, buying an estimated $1.04K and bringing the position to 2,530 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3430.

US Bancorp first reported a position in AQST in Q3 2024 and has held it in 8 quarters since. The position peaked at $27.5K in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • US Bancorp held 2,530 shares of Aquestive Therapeutics worth $10.5K as of Q2 2026.
  • US Bancorp bought 247 Aquestive Therapeutics shares in Q2 2026, an estimated $1.04K.
  • Aquestive Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3430 holding.
  • US Bancorp first reported a position in Aquestive Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • US Bancorp's Aquestive Therapeutics position peaked at $27.5K in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.